SCHEMBL2776763

SCHEMBL2776763

CCOC(=O)c1c(-c2c(F)cccc2Cl)noc1CBr

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.62
TP53 P04637 1/20 0.62
HPGD P15428 3/20 0.56
TSHR P16473 2/20 0.56
MAPK1 P28482 1/20 0.56
ALDH1A1 P00352 3/20 0.54
GAA P10253 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.53
KMT2A Q03164 4/20 0.52
POLB P06746 2/20 0.52
MEN1 O00255 2/20 0.52
HTT P42858 1/20 0.52
ESR1 P03372 1/20 0.52
GPBAR1 Q8TDU6 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
LMNA P02545 3/20 0.51
ATM Q13315 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2775568 0.88 MAPT (0.74) MAPTTP53HPGDTSHRMAPK1
SCHEMBL2774761 0.82 MAPT (0.56) MAPTTP53HPGDTSHRALDH1A1
SCHEMBL30437437 0.81 MAPT (0.60) MAPTTP53HPGDTSHRMAPK1
SCHEMBL19900665 0.81 MAPT (0.60) MAPTTP53HPGDTSHRMAPK1
SCHEMBL16230424 0.80 GHSR (0.52) MAPTTP53HPGDTSHRALDH1A1
SCHEMBL16230423 0.79 POLB (0.50) MAPTTP53HPGDTSHRMAPK1
SCHEMBL16448979 0.79 TSHR (0.66) MAPTTP53HPGDTSHRMAPK1
SCHEMBL6691068 0.79 MAPT (0.61) MAPTTP53HPGDTSHRMAPK1
SCHEMBL11949517 0.79 HPGD (0.60) MAPTTP53HPGDTSHRMAPK1
SCHEMBL5774786 0.78 ALDH1A1 (0.56) MAPTTP53HPGDTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227475-B1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN INC (US) 2014-02-19 EP disclosed
US-8269008-B2 Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions FIBROGEN, INC. (US) 2012-09-18 US disclosed
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2010-12-02 US disclosed
EP-2227475-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS Fibrogen, Inc. (US) 2010-09-15 EP disclosed
WO-2009073669-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS HIF1AN, HIF1A, EGLN2 MAPT 3874/4885TP53 1685/4885HPGD 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.